Primary Safety End Points
bleeding
EVENTS, BLEEDING
A total of 114 bleeding events (5.6%) occurred, including 46 events (6.8%) in the enoxaparin group, 32 (4.7%) in the rivaroxaban 2.5 mg group, and 36 (5.3%) in the rivaroxaban 5 mg group. After 6 months of follow-up, noninferiority of rivaroxaban vs enoxaparin was reached for primary safety end points, in that the upper boundary of the 95% CI of the HR in bleeding events was below the predefined margin (rivaroxaban 2.5 mg: HR, 0.68; 95% CI, 0.43-1.07; 